澳大利亚将从2026年1月开始,将Darzalex药物费用从13K美元降至每月25美元,增加癌症治疗机会。 Australia will slash Darzalex drug costs from $13K to $25 monthly starting Jan 2026, boosting access to cancer treatment.

自2026年1月1日起, 澳洲将大幅提高多种间歇瘤药物(Darzalex)的可负担性, 每月费用由近13 000美元降至25美元, Australia will make the multiple myeloma drug Darzalex significantly more affordable starting January 1, 2026, with monthly costs dropping from nearly $13,000 to $25, thanks to a new subsidy under the Pharmaceutical Benefits Scheme. 这一行动扩大了获得延长生命治疗的机会,每年进行大约2 600次诊断,提高了存活率,减轻了财政压力。 The move expands access to life-extending treatment for around 2,600 annual diagnoses, improving survival rates and reducing financial strain. 政府的行动是更广泛地努力提高关键癌症和慢性病疗法的可负担性的一部分,目前有几个新疗法被列入公共银行数据库。 The government’s action is part of broader efforts to increase affordability of critical cancer and chronic disease therapies, with several new treatments now listed on the PBS.